From Pharmacy to Laboratory
Joachim Messing, known as "Jo" (pronounced yoh), grew up in the town of Duisburg, Germany, in the aftermath of World War II. The first person in his family to go to college, he decided to study pharmacy as an undergraduate. At that time, a degree in biochemistry was not an option for undergraduates. Pharmacy appealed to Messing, in part, because the curriculum covered a broad range of subjects, including organic and inorganic chemistry, botany, and even physics. "You had to learn how to look under the microscope and draw cells," Messing recalls, "you had to learn about the different pathways in plants that make important substances that could be used for therapy. . .you had everything." Studying pharmacy would also allow him to earn money to pay for his education by working as a pharmacist.
For the first two years of the pharmacy curriculum, Messing had to work as a pharmacist's apprentice. The pharmacy where he did his apprenticeship was across from the German Opera on the Rhine in Duisburg. In the evenings, after working at the pharmacy, he would work as an extra with the opera company. The high point of his opera career, Messing says, was getting to carry the actress playing Gilda down a flight of stairs in a production of Rigoletto.
Messing received a bachelor's degree in pharmacy in 1968 and a master's degree in pharmacy in 1971. When he decided to pursue a doctorate in biochemistry, he met with the biochemist Feodor Lynen, who had won the Nobel Prize in 1964 for work on cholesterol and fatty acid metabolism. Lynen advised Messing not to go into Lynen's own field, where much of the important work had already been done. Lynen then told Messing that the future would be in DNA, and arranged for Messing to work in a laboratory studying DNA at the Max Planck Institute for Biochemistry in Munich.
Beginning of Shotgun Sequencing
For his graduate research, Messing studied DNA replication, and got off to what he calls "a lucky start." At that time, it was known that the enzyme DNA polymerase required a primer to begin DNA replication, but the identity of the primer was unknown. Early on in his graduate research, Messing learned about a plasmid that could replicate in the absence of protein synthesis. He quickly demonstrated that the same plasmid could not replicate in the absence of RNA synthesis, suggesting that RNA acted as a primer for DNA polymerase. "That was probably the first evidence of a noncoding RNA in vivo," Messing explains. The finding was published in Nature New Biology, only three months after Messing began his graduate research (1).
Messing received his doctorate in biochemistry from the Ludwig Maximillian University of Munich in 1975. After that time, he stayed on as a research fellow at the Max Planck Institute, where he began the work that would lead to shotgun sequencing. In 1974, while still working on his doctorate, Messing attended a conference on restriction enzymes in Ghent, Belgium, where Frederick Sanger reported on his efforts to sequence the single-stranded genome of bacteriophage ΦΧ174. Sanger was using a time-consuming procedure that involved cleaving the double-stranded version of the phage DNA with a restriction enzyme, separating the fragments by gel electrophoresis, extracting each fragment from the gel, denaturing the fragments, and using the denatured fragments as primers on the viral singlestranded DNA for sequencing by DNA synthesis. Messing thought that the sequencing process could be accelerated by cloning each fragment into a single-stranded DNA phage vector. In this way, all of the fragments could be sequenced in parallel, each using the same primer.
There was just one obstacle-a suitable vector did not yet exist, so Messing had to create one. A suitable vector had to provide a means of rapidly detecting cells containing the cloned inserts. For this purpose, Messing developed the blue-white screen, in which a gene on the vector turns bacterial colonies blue when grown on a special medium unless the vector contains a cloned insert. The first intermediate to incorporate the visible marker, M13mp1, was published in PNAS in 1977 (2). Next, Messing had to insert an artificial restriction site for cloning DNA fragments into the visible marker gene. The gene contained a sequence that differed from a restriction site by only one nucleotide; it had a G instead of an A. Methylation of the G base induced mispairing, which converted the G to A in subsequent rounds of replication. "I think the biggest moment in all the research that I've done was certainly the day when I went into the darkroom to look at. . .whether the restriction site was there or not in the right place," Messing recalls. "It was unusual timing because, a week later, I had to go to the Cold Spring Harbor phage meeting. . . and you never have things that work in time [for meetings]. . . but in this case, it really worked like a charm." The results were published in Nature in early 1978 (3).
Move to the United States and Plant Genetics
In 1978, Messing moved to the University of California, San Francisco for a few months, and then to the University of California, Davis, where he continued to refine his shotgun sequencing system. With the help of researchers at the biotechnology firm Genentech, he developed synthetic oligonucleotide primers and used synthetic DNA adapters to introduce multiple restriction sites into the phage vector, allowing different types of restriction fragments to be cloned (4) . In the first successful demonstration of the shotgun sequencing method, Messing and a plant pathologist, Robert Shepherd, sequenced the 8-kb genome of the cauliflower mosaic virus (5) . By that time, Messing had taken a faculty position at the University of Minnesota.
Meanwhile, Messing began applying the techniques he had developed to the study of plant genetics. "I saw left and right how people said 'well, the future is going to be in eukaryotic DNA, you can't keep working with microbes,'" Messing recalls. Studying plants appealed to him, in part, because of his pharmacy background, and also because of the potential practical applications for nutrition. Messing contributed to sequencing the genomes of crops such as rice, sorghum, and maize. His work has led to the development of corn cultivars with improved levels of the essential amino acids lysine and methionine, and to pest-resistant crop strains.
In 1983, the Waksman Institute of Microbiology at Rutgers University sent Messing an offer to become their new research director. Recognizing the name, Messing dug through some old photographs and found one of himself as an undergraduate with Selman Waksman, the institute's namesake, who had won the Nobel Prize in 1952 for methods leading to the discovery of streptomycin, the first antibiotic treatment for tuberculosis. "So I said to my wife, 'oh, you know, maybe I should have a look,'" he recalls. Messing decided to come to Rutgers because he felt it was a place where he could really make an impact. Messing arrived at Rutgers in 1985, where, in addition to taking over the directorship of the Waksman Institute, he was also tenured as a university professor.
New Frontiers
Today, Messing continues to expand the possibilities of genome sequencing. In his Inaugural Article (6), he reports testing a single-molecule sequencing platform from the sequencing company Pacific Biosciences that can sequence very long stretches of DNA in the maize genome. Eukaryotic genomes contain many duplicate sequences, which prevent the reassembly of entire chromosomal regions from sequenced fragments if the fragments are too short. The new platform overcomes this difficulty and could become important for studies of the human genome and of diseases such as cancer. According to Messing, the greatest challenge was finding a computer cluster powerful enough to handle the massive amounts of data produced. Ultimately, Messing and his colleagues had to enlist the help of Amazon's computing services. The study illustrated that advances in sequencing have come not only from the development and implementation of new techniques but also from progress in computing power.
Messing's contributions to DNA sequencing and plant genetic engineering have won him numerous awards, including the 2013 Wolf Prize in Agriculture and the 2014 Promega Biotechnology Research Award. In 1991, the Institute for Scientific Information in Philadelphia declared him the world's most cited scientist of the previous decade. Messing gets great satisfaction from the knowledge that his work has made possible subsequent life-saving developments, such as the production of recombinant erythropoietin for treating anemia following chemotherapy. "There is no doubt," he says, "that genome sequencing and engineered genes had an unforeseen impact on prolonging life through diagnosis and treatment, saving people from starvation, and improving the quality of life through a greener environment" (7) .
